Get the Stockscreener App
2.73
5.86%
-0.17
After Hours:
2.66
-0.07
-2.56%
Compass Therapeutics Inc Stock (CMPX) Latest News
Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada
Compass Therapeutics shares rise on pipeline progress - Investing.com
Compass Therapeutics Reports 2024 Financial Results - TipRanks
Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks
Compass Therapeutics, Inc. SEC 10-K Report - TradingView
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq
Compass stock gains amid Guggenheim buy rating - MSN
Compass stock gains amid Guggenheim buy rating (CMPX:NASDAQ) - Seeking Alpha
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Compass Therapeutics: Good Execution, Major Catalysts Ahead (NASDAQ:CMPX) - Seeking Alpha
Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target -February 24, 2025 at 07:24 am EST - Marketscreener.com
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Piper Sandler - MarketBeat
Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer - The Globe and Mail
Piper Sandler Initiates Coverage of Compass Therapeutics (CMPX) with Overweight Recommendation - Nasdaq
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Piper Sandler Initiates Compass Therapeutics at Overweight -February 19, 2025 at 09:07 am EST - Marketscreener.com
Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating - TradingView
Piper Sandler sets $12 target on Compass Therapeutics stock By Investing.com - Investing.com UK
Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline - TipRanks
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - MarketBeat
Chronic Pulmonary Hypertension Market Expected to rise, 2034 | COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market - The Globe and Mail
Compass Therapeutics (NASDAQ:CMPX) Trading Down 7.6%Here's Why - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Leerink Partnrs Has Strong Outlook for CMPX FY2024 Earnings - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by Bleakley Financial Group LLC - Defense World
Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow - The Globe and Mail
Organon (OGN) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Molson Coors (TAP) Q4 Earnings: What To Expect - The Globe and Mail
Procter & Gamble Co: Rising -7.15% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Jefferies Financial Group Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):